Skip to content
Conditions & Health

Sarcopenia

Age-related loss of skeletal muscle mass and strength that typically begins after age 30, accelerating after 60. Peptides targeting GH secretion (ipamorelin, CJC-1295) and myostatin inhibition (follistatin) are studied as interventions.

Frequently Asked Questions

What is Sarcopenia?
Age-related loss of skeletal muscle mass and strength that typically begins after age 30, accelerating after 60. Peptides targeting GH secretion (ipamorelin, CJC-1295) and myostatin inhibition (follistatin) are studied as interventions.
Why is Sarcopenia important in peptide research?
Understanding sarcopenia is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

Myostatin

A protein (GDF-8) that negatively regulates skeletal muscle growth. Inhibiting myostatin via follistatin or myostatin antibodies allows greater muscle hypertrophy. Myostatin-knockout animals show dramatic muscle growth.

Growth hormone secretagogue

A compound that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor or GHRH receptor. Includes peptides (ipamorelin, GHRP-2, GHRP-6) and the oral compound MK-677.

IGF-1

Insulin-like growth factor 1, a hormone produced primarily by the liver in response to growth hormone. Mediates many of GH’s anabolic effects including muscle growth, bone density, and tissue repair.

Related Peptide Profiles

Ipamorelin

A selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor with minimal effect on cortisol or prolactin.

Follistatin

A glycoprotein that inhibits myostatin and activin, promoting muscle growth. Studied for its role in muscle hypertrophy and metabolic regulation.

MK-677

Ibutamoren, an oral growth hormone secretagogue that mimics ghrelin signaling to increase GH and IGF-1 levels over 24 hours.

← Back to full glossary